ESR1 and breast carcinoma: However, a less pronounced reduction in the percentages of Ki-67-positive tumor cells was also observed in ER-positive, HER2-positive breast cancer following therapy with the four-drug regimen of trastuzumab, pertuzumab, palbociclib, and fulvestrant18.